Curon is a biopharmaceutical company dedicated to developing the next generation cancer therapies. The company is currently focusing on immuno-oncology and targeted therapies to address unmet medical needs and provide effective treatment options for cancer patients all over the world.
Since its inception in 2018, Curon has established a seasoned executive team with extensive experience in drug discovery, translational research, pre-clinical and clinical development.
With the experienced team, and strong financial support from prestigious investors, Curon strives to become a reputable biopharmaceutical company in providing patients with effective treatment options worldwide.
